EyePoint, Inc.

Contributing Author

Recent Articles by EyePoint, Inc.

6 hours

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema EYPT +6.32% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.